Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Chinese Subjects With Active Systemic Lupus Erythematosus

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
Indications Systemic lupus erythematosus
Focus Registrational; Therapeutic Use
Acronyms LOTUS-C
Sponsors Janssen Research & Development

Most Recent Events

21 Oct 2020 Planned initiation date changed from 5 Jun 2020 to 14 Jul 2020.
26 Jun 2020 According to a Janssen Pharmaceutical media release, the company has withdrawn this LOTUS-C study, based on the discontinuation the LOTUS study due to lack of efficacy
26 Jun 2020 Status changed from not yet recruiting to withdrawn prior to enrolment, according to a Janssen Pharmaceutical media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com